Zapata-González A, Castillo-Chavira G, Camacho-Trejo VF, Schwartz-Velazco A, Ibáñez JA

Language: Spanish
References: 11
Page: 49-52
PDF size: 201.05 Kb.

ABSTRACT

Premature ejaculation is defined as the time between intravaginal penetration and intravaginal ejaculation. Based on this we compared the use of 20 mg of paroxetine as sporadic treatment (administered 6 to 8 hours before coitus) versus continued treatment with the objective of evaluating the therapeutic results of both modalities. Our hypothesis was that they have similar effects.
Materials and Methods: A prospective study was carried out on 20 patients divided into 2 groups of 10 patients each. Intravaginal ejaculation latency time (IELT) and coital frequency were registered prior to treatment. Group A received paroxetine daily for 4 weeks and on request (sporadically) for 4 weeks more and then were treated with placebo. Group B was given placebo in the same manner and then treated with paroxetine. Results were statistically analyzed using the Student t test.
Results: Mean IELT prior to treatment was 0.59 min in Group A and 0.44 min in Group B. Mean pre-treatment coital frequency was 3.1 times per week for Group A and 2.9 for Group B.
Mean IELT was 5.6 min after paroxetine continued treatment and 5.9 min after sporadic treatment in Group A. Mean IELT with daily placebo was 0.5 min and with sporadic placebo was 0.6 min (p‹0.001). Coital frequency increased to 3.7 per week. With daily placebo mean IELT was 0.7 min and with sporadic placebo was 1 min in Group B. With daily paroxetine mean IELT was 3.9 min and with sporadic paroxetine was 5.8 min (p‹0.001). Post-treatment coital frequency increased to 3.9 times per week.
Only 3 patients presented with anxiety as a side effect of the medication.
Conclusions: The results of premature ejaculation treatment with paroxetine are similar with both continued and sporadic administration. The sex life of patients improved and they reported greater satisfaction with sporadic treatment.

REFERENCES

1. Waldinger MD. Lifelong premature ejaculation: definition, serotonergic neurotransmission and drug treatment. World J Urol 2005;23(2):102-8.

2. Waldinger M. Lifelong premature ejaculation: from authority-based to evidence based medicine. BJU Int 2004;93(9):201-7.

3. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Proposal for a definition of lifelong premature ejaculation based on epidemiological stopwatch data. J Sex Med 2005;2(4):489-509.

4. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. Washington, DC: APA.

5. Waldinger MD. Towards evidence based drug treatment research on premature ejaculation: a critical evaluation of methodology. Int J Impot Res 2003;15(5):309-13.

6. Waldinger MD. Premature ejaculation: different pathophysiologies and etiologies determine its treatment. J Sex Marital Ther 2008;34(1):1-13.

7. Waldinger MD, Berendsen HHG, Blok BFM, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998;92:111-8.

8. Waldinger MD. The neurobiological approach to premature ejaculation (review). J Urol 2002;168:2359-67.

9. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of Premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994;151:1377-9.

10. Schapiro B. Premature ejaculation, a review of 1130 cases. J Urol 1943;50:3749.

11. Eaton H. Clomipramine in the treatment of premature ejaculation. J Int Med Res 1973;1:432-4.